Christopher J Burns

This inventor holds 52 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Beta-Lactamase Inhibitors. Top assignees: Venatorx Pharmaceuticals, Inc., Microdose Therapeutx, Inc., Aventis Pharmaceuticals Inc.. Active years: 1994-2026.

USPTO Granted Patents = 52 (Patent Applications = 17)

% Patents Active = 67.3

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 7.0

ph-index = 12

Forward Citations = 411(Granted Patents)

Forward Citations (Not Self Cited) = 147(Dec 10, 2025)

Location History:

Bryn Mawr, PA (US) (1994)
Rosemont, PA (US) (2000 - 2001)
Malvern, PA (US) (2003 - 2024)

Company Filing History:

37 out of 41

Venatorx Pharmaceuticals, Inc.

patents

5 out of 51

Microdose Therapeutx, Inc.

patents

3 out of 207

Aventis Pharmaceuticals Inc.

patents

4. 3 out of 23

Viropharma Incorporated

Rhone-Poulenc Rorer Pharmaceuticals Inc.

patents

7. 1 out of 23

Aventis Pharmaceuticals Products Inc.

patents

8. 1 out of 2

Microdose Therapeutix, Inc.

patents

where one patent can have more than one assignee

Years Active: 1994-2026

Loading Chart...

Areas of Expertise:

Beta-Lactamase Inhibitors

Nucleoside Analogs

Hepatitis B Modulators

Pneumovirus Treatment

Combination Compositions

Penicillin-Binding Proteins

Broad-Spectrum Carbapenems

Solid Forms

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12544395 - Combination compositions comprising a beta-lactamase inhibitor and uses thereof (2026-02-10),

2. 12187752 - Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof (2025-01-07),

3. 12173018 - Penicillin-binding protein inhibitors (2024-12-24),

4. 12102648 - Orally-bioavailable nucleoside analogs (2024-10-01),

5. 12084445 - Broad-spectrum carbapenems (2024-09-10),

6. 11820784 - Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof (2023-11-21),

7. 11638715 - Orally-bioavailable nucleoside analogs (2023-05-02),

8. 11566001 - Hepatitis B capsid assembly modulators (2023-01-31),

9. 11414435 - Beta-lactamase inhibitors (2022-08-16),

10. 11332485 - Penicillin-binding protein inhibitors (2022-05-17),

11. 11267826 - Penicillin-binding protein inhibitors (2022-03-08),

12. 11247965 - Hepatitis B capsid assembly modulators (2022-02-15),

13. 11091505 - Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof (2021-08-17),

14. 11046716 - Beta-lactamase inhibitors (2021-06-29),

15. 11014881 - Hepatitis B capsid assembly modulators (2021-05-25),

Title: The Innovative Journey of Christopher J Burns

Introduction: Christopher J Burns, a talented inventor hailing from Malvern, PA, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Christopher J Burns has recently been granted patents for his cutting-edge inventions in the fields of artificial intelligence and renewable energy technologies.

Career Highlights: With a career spanning over two decades, Christopher J Burns has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing solutions to address them. His work has not only revolutionized industries but has also improved the lives of many around the globe.

Collaborations: Throughout his career, Christopher J Burns has collaborated with leading research institutions, universities, and tech companies to further enhance his inventions and bring them to the market. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Christopher J Burns continues to push the boundaries of innovation, inspiring the next generation of inventors to think outside the box and create solutions that have a lasting impact on society. His dedication to excellence and passion for innovation make him a true pioneer in the world of technology.